BrachySil meets endpoint in liver cancer trial
This article was originally published in Clinica
Executive Summary
A phase IIa clinical trial of pSivida's BioSilicon-based brachytherapy product for treating inoperable primary liver cancer has achieved its primary endpoint by proving to be both safe and well tolerated.